Korean Anti-Cancer Resistance Drug OCT-598 Begins Phase 1 Clinical Trials Through Public-Private Partnership
核心洞察
OCT-598 (搜索), a novel drug candidate targeting cancer treatment resistance through dual EP2 and EP4 receptor inhibition, has initiated Phase 1 clinical trials in Korea and internationally following FDA and MFDS approvals.
The drug demonstrated complete tumor remission in animal studies when combined with standard therapies and showed potential for forming anti-cancer immune memory to prevent recurrence and metastasis.
The development represents a successful "relay research" model where Korea Research Institute of Chemical Technology and Cana Therapeutics (搜索) conducted early discovery, with Oscotec (搜索) advancing clinical development.
A groundbreaking anti-cancer drug candidate designed to overcome treatment resistance has officially entered clinical trials, marking a significant milestone for Korean pharmaceutical innovation. OCT-598 (搜索), jointly developed by the Korea Research Institute of Chemical Technology (KRICT), Cana Therapeutics (搜索), and Oscotec (搜索), has begun Phase 1 clinical trials both domestically and internationally after receiving regulatory approvals from the U.S. FDA and Korea's Ministry of Food and Drug Safety.
Novel Dual-Target Mechanism
OCT-598 (搜索) distinguishes itself through its unique dual inhibition mechanism targeting both EP2 and EP4 receptors, which are key pathways in prostaglandin E2 (PGE2) signaling. This pathway has long been identified as central to the development of cancer cell resistance during treatment. Unlike conventional anti-cancer drugs that often fail to adequately control the tumor microenvironment formed after cancer cell death, OCT-598 employs a strategy that modulates the immunosuppressive environment itself to sustain anti-cancer effects.
In preclinical animal studies, the drug demonstrated remarkable efficacy when used in combination with standard therapies, achieving complete remission (CR) where tumors completely disappeared. The studies also revealed the drug's potential for forming anti-cancer immune memory to suppress recurrence and metastasis, addressing critical challenges in cancer treatment.
Successful Public-Private Collaboration Model
The development of OCT-598 (搜索) represents what industry experts call a "relay research" model, where public and private sectors collaborate in stages. The compound was jointly discovered and validated by KRICT and Cana Therapeutics (搜索) from the early research stages, then transferred to Oscotec (搜索) for accelerated clinical development. With the successful commencement of first patient dosing in the Phase 1 trial, the original developers received milestone payments, demonstrating the translation of research achievements into tangible business value.
Dr. Hansu Bong, the principal investigator at KRICT, emphasized the significance of this approach: "The clinical advancement of OCT-598 (搜索) demonstrates that public research outcomes can reach the patient treatment stage when combined with the development capabilities of venture companies and pharmaceutical firms. The 'relay research' model, in which the public and private sectors divide roles and hand off the baton in stages, can serve as a practical solution to enhance national bio-competitiveness."
Clinical Development Progress
Oscotec (搜索) received Investigational New Drug (IND) approval from the U.S. FDA in May 2025 and from Korea's Ministry of Food and Drug Safety in November of the same year. Major domestic medical institutions are currently evaluating the drug's safety, optimal dosage, and initial efficacy in patients with advanced solid tumors who have developed resistance to existing treatments.
The company plans to formally assess OCT-598 (搜索)'s resistance-overcoming effects through combination therapy with docetaxel, a standard anti-cancer drug for solid tumors. This approach aims to solidify the drug's position as a novel therapy for overcoming anti-cancer resistance.
Industry Implications
Industry experts view the clinical results of OCT-598 (搜索) as a crucial test of the global competitiveness of domestically developed anti-cancer drugs in the field of cancer resistance treatment. The successful division of labor—from initial discovery at KRICT, to optimization and validation by Cana Therapeutics (搜索), to clinical development by Oscotec (搜索)—has functioned as intended, preventing research outcomes from being shelved and increasing the likelihood of commercialization.
This achievement demonstrates that the collaborative model can effectively bridge the gap between academic research and clinical application, potentially serving as a blueprint for future pharmaceutical development initiatives in Korea and beyond.